 United States Food and Drug Administration
"United States Food and Drug Administration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
| Descriptor ID |
D014486
|
| MeSH Number(s) |
I01.409.137.500.600.650.760 N03.540.348.500.500.600.650.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "United States Food and Drug Administration".
Below are MeSH descriptors whose meaning is more specific than "United States Food and Drug Administration".
This graph shows the total number of publications written about "United States Food and Drug Administration" by people in UAMS Profiles by year, and whether "United States Food and Drug Administration" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2022 | 0 | 5 | 5 | | 2021 | 1 | 6 | 7 | | 2020 | 2 | 5 | 7 | | 2019 | 0 | 3 | 3 | | 2018 | 0 | 1 | 1 | | 2017 | 0 | 3 | 3 | | 2016 | 0 | 1 | 1 | | 2015 | 0 | 3 | 3 | | 2014 | 1 | 1 | 2 | | 2013 | 1 | 1 | 2 | | 2012 | 1 | 2 | 3 | | 2011 | 0 | 3 | 3 | | 2010 | 0 | 7 | 7 | | 2009 | 0 | 2 | 2 | | 2008 | 0 | 1 | 1 | | 2007 | 0 | 3 | 3 | | 2006 | 1 | 1 | 2 | | 2005 | 1 | 7 | 8 | | 2004 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2002 | 0 | 4 | 4 | | 2001 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1994 | 1 | 1 | 2 | | 1992 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "United States Food and Drug Administration" by people in Profiles over the past ten years.
-
Burroughs AW, Krain LP. What Might Aducanumab Teach Us About Clinicians' Judgment About Whether to Recommend Emerging Alzheimer's Interventions? AMA J Ethics. 2023 10 01; 25(10):E777-782.
-
Tobacyk J, Parks BJ, Lovelady N, Brents LK. Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom. Int J Drug Policy. 2022 10; 108:103817.
-
Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol. 2022 08; 8:e2200119.
-
Yan J, Datta S, Kesselman A, Malhotra A, Scherer K, Wadhwa V. Adverse Events Associated with New Nitinol Venous-Labeled Stents: A Review of the FDA MAUDE Database. J Vasc Interv Radiol. 2022 10; 33(10):1261-1263.
-
Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
-
Rick JW, Lio P, Hsiao JL, Shi VY. Response to: "Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication". J Am Acad Dermatol. 2022 07; 87(1):e33-e34.
-
Ramai D, DeLuca M, Facciorusso A, Ofosu A, Girotra M, Tabibian JH, Rodrigues-Pinto E, Adler DG, Barakat MT. Analysis of Reported Adverse Events With Colonic Stents: An FDA MAUDE Database Study. J Clin Gastroenterol. 2022 10 01; 56(9):784-786.
-
Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer Invest. 2022 01; 40(1):14-16.
-
Jones DM, Guy MC, Soule E, Sakuma KK, Pokhrel P, Orloff M, Trinidad D, Smith D, Browley S, Walker AP, Bullock S, Eissenberg T, Fagan P. Characterization of Electronic Cigarette Warning Statements Portrayed in YouTube Videos. Nicotine Tob Res. 2021 08 04; 23(8):1358-1366.
-
Wolf J, Abzug MJ, Wattier RL, Sue PK, Vora SB, Zachariah P, Dulek DE, Waghmare A, Olivero R, Downes KJ, James SH, Pinninti SG, Yarbrough A, Aldrich ML, MacBrayne CE, Soma VL, Grapentine SP, Oliveira CR, Hayes M, Kimberlin DW, Jones SB, Bio LL, Morton TH, Hankins JS, Maron GM, Timberlake K, Young JL, Orscheln RC, Schwenk HT, Goldman DL, Groves HE, Huskins WC, Rajapakse NS, Lamb GS, Tribble AC, Lloyd EC, Hersh AL, Thorell EA, Ratner AJ, Chiotos K, Nakamura MM. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. J Pediatric Infect Dis Soc. 2021 May 28; 10(5):629-634.
-
Kearns GL, van den Anker JN. Adolescents and Drug Development: Commentary on a Dawning Paradigm Shift. J Clin Pharmacol. 2021 06; 61(6):740-743.
-
Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524.
-
Fishbein H, Bauer D, Yu Q, Mermelstein R, Jones D, Miller A, Harrell M, Loukas A, Sterling K, Colip B, Mittl B. Harmonizing Cigar Survey Data Across Tobacco Centers of Regulatory Science, Center for Tobacco Products, and Population Assessment of Tobacco and Health Studies: The Cigar Collaborative Research Group. Nicotine Tob Res. 2021 01 07; 23(1):212-218.
-
Chen Z, Liu X, Hogan W, Shenkman E, Bian J. Applications of artificial intelligence in drug development using real-world data. Drug Discov Today. 2021 05; 26(5):1256-1264.
-
Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, Reyes HM, Weiss SR, Frieman MB. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. J Virol. 2020 10 14; 94(21).
-
Koturbash I, MacKay D. Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway. J Diet Suppl. 2020; 17(5):487-492.
-
Fagan P, Eissenberg T, Jones DM, Cohen JE, Nez Henderson P, Clanton MS. The First 10 Years: Reflecting on Opportunities and Challenges of the Tobacco Products Scientific Advisory Committee of the United States Food and Drug Administration. J Leg Med. 2020 Jul-Dec; 40(3-4):293-320.
-
Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Ann Intern Med. 2020 08 18; 173(4):320-322.
-
Walker LA, Koturbash I, Kingston R, ElSohly MA, Yates CR, Gurley BJ, Khan I. Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory Approaches. J Diet Suppl. 2020; 17(5):493-502.
-
Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. Ann Pharmacother. 2020 10; 54(10):1001-1009.
-
Inselman A, Liu F, Wang C, Shi Q, Pang L, Mattes W, White M, Lyn-Cook B, Rosas-Hernandez H, Cuevas E, Lantz S, Imam S, Ali S, Petibone DM, Shemansky JM, Xiong R, Wang Y, Tripathi P, Cao X, Heflich RH, Slikker W. Dr. Daniel Acosta and In Vitro toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research. Toxicol In Vitro. 2020 Apr; 64:104471.
-
Lee GR, Maarouf M, Hendricks AJ, Lee DE, Shi VY. Topical probiotics: the unknowns behind their rising popularity. Dermatol Online J. 2019 May 15; 25(5).
-
Deer T, Kim P, Pope JE, Hayek S, McDowell G, Mekhail N, Diwan S, Saulino M, Moeschler S, Schultz D, Gritsenko K, Prager J, Peterson EA, Staats P, Poree L, Fishman MA, Vallejo R, Calodney A, Slavin K, de Leon Cassadala O, Levy R, Buvanendran A, Sitzman BT, Sayed D, Ferrante FM, Kloth D, Gilligan CJ, Kapural L, Kloster DR, Leong M, Rosenow JM, Lamer TJ, Stearns L. Physician Guidance on the Use of Off-Labeled Drugs in Intrathecal Drug Delivery Systems for Chronic Pain. Neuromodulation. 2019 10; 22(7):765-768.
-
Garza M, Seker E, Zozus M. Development of Data Validation Rules for Therapeutic Area Standard Data Elements in Four Mental Health Domains to Improve the Quality of FDA Submissions. Stud Health Technol Inform. 2019; 257:125-132.
-
McElfish PA, Purvis RS, Stewart MK, James L, Kim Yeary KH, Long CR. Health Research Funding Agencies' Policies, Recommendations, and Tools for Dissemination. Prog Community Health Partnersh. 2018; 12(4):473-482.
-
Simon JE, Decker EA, Ferruzzi MG, Giusti MM, Mejia CD, Goldschmidt M, Talcott ST. Establishing Standards on Colors from Natural Sources. J Food Sci. 2017 Nov; 82(11):2539-2553.
-
Ward RM, Benjamin DK, Davis JM, Gorman RL, Kauffman R, Kearns GL, Murphy MD, Sherwin CMT. The Need for Pediatric Drug Development. J Pediatr. 2018 01; 192:13-21.
-
Wadhwa V, Trivedi PS, Chatterjee K, Tamrazi A, Hong K, Lessne ML, Ryu RK. Decreasing Utilization of Inferior Vena Cava Filters?in Post-FDA Warning Era: Insights From 2005 to 2014 Nationwide Inpatient Sample. J Am Coll Radiol. 2017 Sep; 14(9):1144-1150.
-
Hill KD, Goldstein BH, Angtuaco MJ, Chu PY, Fleming GA. Post-market surveillance to detect adverse events associated with Melody? valve implantation. Cardiol Young. 2017 Aug; 27(6):1090-1097.
-
Singh VK, Newman VL, Romaine PL, Hauer-Jensen M, Pollard HB. Use of biomarkers for assessing radiation injury and efficacy of countermeasures. Expert Rev Mol Diagn. 2016; 16(1):65-81.
-
Donny EC, Denlinger RL, Tidey JW, Koopmeiners JS, Benowitz NL, Vandrey RG, al'Absi M, Carmella SG, Cinciripini PM, Dermody SS, Drobes DJ, Hecht SS, Jensen J, Lane T, Le CT, McClernon FJ, Montoya ID, Murphy SE, Robinson JD, Stitzer ML, Strasser AA, Tindle H, Hatsukami DK. Randomized Trial of Reduced-Nicotine Standards for Cigarettes. N Engl J Med. 2015 Oct; 373(14):1340-9.
-
Torok NJ, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology. 2015 Aug; 62(2):627-34.
-
Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014 Oct 01; 20(19):4994-5000.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|